9 results on '"Benites, Bruno Deltreggia"'
Search Results
2. The challenges of handling deferasirox in sickle cell disease patients older than 40 years.
- Author
-
Ribeiro, Lorena Bedotti, Soares, Eliane Alves, Costa, Fernando Ferreira, Gilli, Simone Cristina Olenscki, Olalla Saad, Sara Teresinha, and Benites, Bruno Deltreggia
- Subjects
SICKLE cell anemia ,OLDER patients ,IRON chelates ,BLOOD transfusion reaction - Abstract
Objectives: Deferasirox is an oral iron chelator with established dose-dependent efficacy for the treatment of iron overload secondary to transfusion. However, there is few data reporting the use of Desferasirox in adult patients with sickle cell disease (SCD) and transfusional iron overload. Methods: We conducted a prospective, single center, nonrandomized study from January 2014 to March 2015 in Campinas, Brazil. Seven patients (five women, median age 50 y.o.) who were followed up on regular transfusion program were treated with a single daily dose of deferasirox (median dose 20 mg/kg). They were monitored for clinical symptoms, renal function and hepatotoxicity. Results: One patient discontinued the study due to lack of compliance. Two patients reported mild to moderate adverse events (gastrointestinal disturbances). Five patients had the drug discontinued due to worsening of renal function. One patient had the drug discontinued due to severe hepatotoxicity that evolved to death; no patient finished the study. Discussion and conclusions: Deferasirox does not appear to be well tolerated in SCD patients older than 40 years, in which complications of the underlying disease are already fully installed. The choice of the ideal iron chelator for this population should include an evaluation of comorbidities and organic dysfunctions, as well as the need to find pharmacogenetic safety markers in this group of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Sickle cell/ß-thalassemia : comparison of Sß0 and Sß+ brazilian patients followed at a single institution
- Author
-
Benites, Bruno Deltreggia, 1984, Ramos, Celso Darío, 1964, Costa, Fernando Ferreira, 1950, Gilli, Simone Cristina Olenscki, Saad, Sara Teresinha Olalla, 1956, and UNIVERSIDADE ESTADUAL DE CAMPINAS
- Subjects
ß-thalassemia ,Sickle cell anemia ,Artigo original ,Clinical features ,Anemia falciforme - Abstract
In sickle cell/ß-thalassemia, mutations in the corresponding ß-globin genes are responsible for complex pathological events resulting in diverse clinical complications. The objective of this study was to provide an overview of the clinical and laboratory characteristics of patients with the syndrome, and of the degree of severity of clinical manifestations resulting from the ß-thalassemia mutation. A retrospective chart review was performed on 46 patients with sickle cell/ß-thalassemia (31 Sß° and 15 Sß+), evaluating hematological parameters and end organ damage. Statistical analyzes were carried out in order to highlight differences between the two groups according to the nature of the thalassemia mutation. As expected, patients with the Sß0 phenotype had a higher degree of hematological involvement in comparison to Sß+ patients; with lower hemoglobin levels, and signs of more intense chronic hemolysis. However, Sß+ patients were more prone to the occurrence of acute chest syndrome. The impact of the thalassemia mutation upon total body and bone composition was also evident, as Sß0 patients presented lower body mass index (BMI) and bone mineral density. The degree of bone damage correlated to lower BMI and hemoglobin levels, as well as plaquetosis, monocytosis and elevated lactate dehydrogenase, possibly reflecting the effects of hemolysis and inflammation upon bone metabolism and body constitution. This study identified significant differences among sickle cell/ß-thalassemia patients according to the beta mutation involvement, pointing to an important predictor of disease severity Fechado
- Published
- 2016
4. Myocardial Iron Overload in Sickle Cell Disease: A Rare But Potentially Fatal Complication of Transfusion.
- Author
-
Tavares, Alvaro Henrique Junqueira, Benites, Bruno Deltreggia, and Fertrin, Kleber Yotsumoto
- Abstract
Sickle cell disease (SCD) is a frequent indication for chronic transfusion, which can cause iron overload. Excess iron often affects the liver, but not the heart in SCD. Magnetic resonance (MR) is recommended to detect myocardial iron overload (MIO) but its elevated cost requires optimized indication. We aimed to compile all published data on MIO in SCD upon the description of a fatal case of severe MIO in our institution, and to determine associated risk factors. We performed a systematic review using the PRISMA guidelines in two databases (PubMed and Web of Science). Inclusion criteria were publication in English, patients diagnosed with SCD, and reporting ferritin and MIO by MR. Twenty publications reported on 865 SCD adult and pediatric patients, with at least 10 other cases of MIO. The prevalence of MIO in chronically transfused SCD patients can be estimated to be 3% or less, and is associated with high transfusion burden, top-up transfusions, and low adherence to iron chelation. Cardiac siderosis in SCD is rarely reported, and increased awareness with better use of the available screening tools are necessary. Prospective studies should define the recommended chelation regimens depending on the severity of MIO. • Chronic transfusions can lead to liver and heart iron overload. • Myocardial iron overload is rare, but can be fatal in sickle cell disease. • Transfusion burden and low compliance to chelation are possible risk factors. • Increased awareness and better screening for iron overload are necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the −1774delG polymorphism in the Abcc2 gene.
- Author
-
Braga, Caroline C. B., Benites, Bruno Deltreggia, Albuquerque, Dulcineia M., Alvarez, Marisa C., Seva‐Pereira, Tiago, Duarte, Bruno K. L., Costa, Fernando F., Gilli, Simone C. O., and Saad, Sara T. O.
- Subjects
- *
SICKLE cell anemia , *HEPATITIS , *LIVER failure , *HEPATOTOXICOLOGY , *PATIENTS , *THERAPEUTICS ,THERAPEUTIC use of iron chelates - Abstract
Key Clinical Message This manuscript describes the case of a patient with sickle cell anemia who died of fulminant hepatitis after therapy with the iron chelator Deferasirox. The patient was homozygous for the −1774delG polymorphism in the Abcc2 gene, which raises the concern about the use of hepatotoxic drugs in this specific context. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Sickle cell/β-thalassemia: Comparison of Sβo and Sβ+ Brazilian patients followed at a single institution.
- Author
-
Benites, Bruno Deltreggia, Bastos, Stephany Oliveira, Baldanzi, Gabriel, dos Santos, Allan de Oliveira, Ramos, Celso Dario, Costa, Fernando Ferreira, Gilli, Simone Cristina Olenscki, and Saad, Sara Teresinha Olalla
- Subjects
- *
SICKLE cell anemia , *GENETICS of thalassemia , *GENETIC mutation , *HEMATOLOGY , *GLOBIN genes , *BRAZILIANS , *GENETICS , *DISEASES - Abstract
Objectives: In sickle cell/β-thalassemia, mutations in the corresponding β-globin genes are responsible for complex pathological events resulting in diverse clinical complications. The objective of this study was to provide an overview of the clinical and laboratory characteristics of patients with the syndrome, and of the degree of severity of clinical manifestations resulting from the β-thalassemia mutation. Methods: A retrospective chart review was performed on 46 patients with sickle cell/β-thalassemia (31 Sβo and 15 Sβ+), evaluating hematological parameters and end organ damage. Statistical analyzes were carried out in order to highlight differences between the two groups according to the nature of the thalassemia mutation. Results: As expected, patients with the Sβo phenotype had a higher degree of hematological involvement in comparison to Sβ+ patients; with lower hemoglobin levels, and signs of more intense chronic hemolysis. However, Sβ+ patients were more prone to the occurrence of acute chest syndrome. The impact of the thalassemia mutation upon total body and bone composition was also evident, as Sβo patients presented lower body mass index (BMI) and bone mineral density. The degree of bone damage correlated to lower BMI and hemoglobin levels, as well as plaquetosis, monocytosis and elevated lactate dehydrogenase, possibly reflecting the effects of hemolysis and inflammation upon bone metabolism and body constitution. Conclusions: This study identified significant differences among sickle cell/β-thalassemia patients according to the beta mutation involvement, pointing to an important predictor of disease severity. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. The effects of exchange transfusion for prevention of complications during pregnancy of sickle hemoglobin C disease patients.
- Author
-
Benites, Bruno Deltreggia, Benevides, Thais Celi Lopes, Valente, Isabella Salvetti, Marques, Jose Francisco, Gilli, Simone Cristina Olenscki, and Saad, Sara Teresinha Olalla
- Subjects
- *
BLOOD transfusion , *PREGNANCY complications , *SICKLE cell anemia , *GESTATIONAL age , *HEALTH outcome assessment , *PREVENTION , *BLOOD disease treatment , *COMPARATIVE studies , *RED blood cell transfusion , *HEMAPHERESIS , *RESEARCH methodology , *MEDICAL cooperation , *PRENATAL care , *RESEARCH , *EVALUATION research , *TREATMENT effectiveness ,PREVENTION of pregnancy complications ,TREATMENT of pregnancy complications - Abstract
Background: Pregnancy represents a challenge for women with sickle cell disease (SCD), with higher rates of both maternal and fetal complications. The aim of this study was to evaluate the impact of prophylactic transfusion support administered specifically to pregnant women with sickle hemoglobin C disease.Materials and Methods: Patients were divided into two groups according to the type of transfusion support received: 10 women received prophylactic erythrocytapheresis or manual exchange transfusion at 28 weeks of gestation, and 14 received transfusions only on demand, due to acute complications, or received no transfusions at all.Results: Our results indicated higher frequencies of SCD-related complications in the group that did not receive prophylactic transfusion support (35.7% vs. only 10% in the erythrocytapheresis group). Furthermore, these complications were more severe in this group and included all cases of acute chest syndrome. A significant difference was observed concerning gestational age at birth (38.7 weeks in the transfusion group vs. 34.4 weeks, p = 0.037), with a higher frequency of preterm births in the nontransfused group (69.23% vs. 30% in the transfusion group).Conclusion: We demonstrated a clear reduction of unfavorable outcomes in patients receiving prophylactic transfusions, probably reflecting better maternal and fetal conditions, which corroborated to the more satisfactory indices of vitality, observed in newborns. Considering that erythrocytapheresis or manual exchange transfusions both represent feasible and safe procedures, they could represent important tools for the optimal management of these patients. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
8. Cytokine polymorphisms in sickle cell disease and the relationship with cytokine expression.
- Author
-
Olenscki Gilli, Simone Cristina, Pericole, Fernando Vieira, Benites, Bruno Deltreggia, Sippert, Emilia Ângela, Castilho, Lilian Maria, Addas-Carvalho, Marcelo, and Olalla Saad, Sara Teresinha
- Subjects
- *
FIBRINOGEN polymorphisms , *SICKLE cell anemia , *CYTOKINES , *GENETIC polymorphisms , *GENE expression - Abstract
Sickle cell disease is a chronic inflammatory condition characterized by elevated levels of inflammatory cytokines, which may be regulated by genetic polymorphisms and could be associated with diverse disease presentations and alloimmunization. The aim of this study was to evaluate Treg and Th17 cell frequencies, cytokine gene polymorphisms, and their association with cytokine expression profile in patients with sickle cell disease. For that purpose, we evaluated the IL intron 3 variable number tandem repeat (VNTR, genotypes 1.1, 1.2, 2.2, and 2.3), IL4-T590C>T, IL6-174G>C, TNFα-308G>A, IL10-819T>C, IL10-592A>C, and IL10-1082A>G polymorphisms and their correlation with TGFβ, IL4, IL6, and IL10 gene expression in sickle cell patients. We observed a significant decrease in Treg frequency together with a substantial increase in Th17 response in patients with sickle cell disease compared with healthy controls ( p < 0.001 and p = 0.014, respectively). There was also a higher prevalence of the IL4-590T/T genotype in patients with sickle cell disease than in Afro-Brazilian descendent controls ( p < 0.001) and higher expression of IL4 in patients with the 1.1 genotype of IL4 intron 3 VNTR ( p = 0.06). Significantly greater gene expression of TGFβ, IL6, and IL10 was observed in sickle cell patients when compared with controls ( p = 0.01, 0.03, and <0.001, respectively). Moreover, higher levels of interleukin-6 and -10 were observed in the group of alloimmunized patients. These new data bring insights into the deregulation in the immune system affecting sickle cell patients and must be further investigated in larger cohorts to better characterize individual variations in immune responses and new markers for disease morbidity. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Platelet counts on peripheral blood and Mean Platelet Volume as markers of clinical severity in Sickle Cell Disease.
- Author
-
Silva, Caroline Martins, de Souza Medina, Samuel, de Melo Campos, Paula, Costa, Fernando Ferreira, Saad, Sara Teresinha Olalla, and Benites, Bruno Deltreggia
- Subjects
- *
MEAN platelet volume , *SICKLE cell anemia , *PLATELET count , *BIOMARKERS - Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.